Vitro Biopharma's Q3 Revenue Soars, But Net Loss Widens on Debt Costs

TL;DR

**Vitro Biopharma is a high-risk bet: strong revenue growth is overshadowed by a ballooning deficit and massive convertible debt, making it a speculative play for aggressive traders only.**

AI Summary

Vitro Biopharma, Inc. reported a significant increase in total revenue for the three months ended July 31, 2025, reaching $608,643, up from $319,909 in the prior year, representing a 90.2% increase. For the nine months ended July 31, 2025, total revenue grew to $1,570,101 from $1,317,056, a 19.2% increase. Despite revenue growth, the company's net loss widened considerably for the three-month period, from $(149,080) in 2024 to $(1,698,538) in 2025, primarily due to a substantial increase in derivative/warrant liability from $154,966 to $5,154,391 and higher interest expense. The nine-month net loss improved slightly from $(7,837,185) to $(6,011,986). Cash decreased significantly from $571,360 at October 31, 2024, to $175,081 at July 31, 2025. The company issued $5,675,000 in 2025 Series Senior Secured Convertible Notes Payable and paid down $4,370,000 of 2024 Series notes, indicating active debt management but also a reliance on convertible debt for financing. Total liabilities surged from $14,090,020 to $16,707,634, exacerbating the stockholders' deficit to $(12,078,921).

Why It Matters

Vitro Biopharma's substantial revenue growth, particularly the 90.2% increase in Q3 2025 product sales, signals potential market traction for its biopharmaceutical products. However, the dramatic increase in net loss for the quarter, driven by a massive derivative/warrant liability and high interest expenses, raises significant concerns about financial stability and dilution risk for investors. The company's heavy reliance on convertible notes, including the new $5,675,000 2025 Series, suggests ongoing funding challenges and could lead to further stock dilution, impacting existing shareholders. Competitors in the biopharma space with stronger balance sheets may gain an advantage, while employees face uncertainty given the growing accumulated deficit of $(43,961,679).

Risk Assessment

Risk Level: high — The company's total liabilities increased from $14,090,020 to $16,707,634, and its stockholders' deficit deepened from $(9,000,973) to $(12,078,921) between October 31, 2024, and July 31, 2025. A significant derivative/warrant liability of $5,154,391, up from $154,966, indicates substantial financial complexity and potential future dilution or cash outflows.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the implications of the company's substantial convertible debt and derivative liabilities. Given the high risk and increasing deficit, a 'wait and see' approach is advisable, focusing on future filings for signs of improved financial health and reduced reliance on dilutive financing.

Financial Highlights

debt To Equity

N/A

revenue

$608,643

operating Margin

N/A

total Assets

N/A

total Debt

$16,707,634

net Income

$(1,698,538)

eps

N/A

gross Margin

N/A

cash Position

$175,081

revenue Growth

+90.2%

Revenue Breakdown

Key Numbers

• $608,643 — Total Revenue (Q3 2025) (Increased 90.2% from $319,909 in Q3 2024)
• $(1,698,538) — Net Loss (Q3 2025) (Widened significantly from $(149,080) in Q3 2024)
• $1,570,101 — Total Revenue (YTD Q3 2025) (Increased 19.2% from $1,317,056 in YTD Q3 2024)
• $(6,011,986) — Net Loss (YTD Q3 2025) (Improved from $(7,837,185) in YTD Q3 2024)
• $175,081 — Cash Balance (Decreased from $571,360 at October 31, 2024)
• $5,154,391 — Derivative/Warrant Liability (Increased from $154,966 at October 31, 2024)
• $16,707,634 — Total Liabilities (Increased from $14,090,020 at October 31, 2024)
• $(12,078,921) — Total Stockholders' (Deficit) (Deepened from $(9,000,973) at October 31, 2024)
• $5,675,000 — 2025 Series Senior Secured Convertible Notes Payable (Issued during the nine months ended July 31, 2025)
• 4,460,535 — Common Stock Shares Outstanding (Consistent across periods, but potential for future dilution from convertible notes)

Key Players & Entities

• Vitro Biopharma, Inc. (company) — Registrant
• Dr. Jack Zamora (person) — Former Chief Executive Officer and President, 30% stockholder, and related party customer
• Fitore, Inc. (company) — Wholly owned subsidiary of Vitro Biopharma, Inc.
• InfiniVive MD, LLC (company) — Wholly owned subsidiary of Vitro Biopharma, Inc.
• SEC (regulator) — Securities and Exchange Commission
• $608,643 (dollar_amount) — Total revenue for the three months ended July 31, 2025
• $1,698,538 (dollar_amount) — Net loss for the three months ended July 31, 2025
• $5,154,391 (dollar_amount) — Derivative/Warrant Liability as of July 31, 2025
• $5,675,000 (dollar_amount) — Issuance of 2025 Series Senior Secured Convertible Notes Payable
• $12,078,921 (dollar_amount) — Total Stockholders' (Deficit) as of July 31, 2025

FAQ

Risk Factors

• Widening Net Loss and Deteriorating Cash Position [high — financial]: The company reported a net loss of $(1,698,538) for Q3 2025, a significant increase from $(149,080) in Q3 2024. This is coupled with a sharp decline in cash from $571,360 to $175,081, raising concerns about liquidity and operational sustainability.
• Increased Derivative and Warrant Liability [high — financial]: The derivative/warrant liability surged from $154,966 to $5,154,391, a substantial increase that contributed significantly to the widened net loss in Q3 2025. This indicates potential future dilution or financial obligations.
• Growing Total Liabilities and Stockholders' Deficit [high — financial]: Total liabilities increased from $14,090,020 to $16,707,634, while the stockholders' deficit deepened to $(12,078,921). This indicates a worsening financial structure and increased financial risk.
• Reliance on Convertible Debt Financing [medium — financial]: The issuance of $5,675,000 in 2025 Series Senior Secured Convertible Notes Payable highlights a reliance on debt financing, which carries interest obligations and potential future equity dilution upon conversion.
• Unexplained Revenue Drivers [medium — operational]: While revenue increased significantly by 90.2% in Q3 2025, the specific drivers for this growth are not detailed in the provided summary. Understanding the sustainability and source of this revenue is crucial.
• Increased Interest Expense [medium — financial]: Higher interest expense contributed to the widened net loss in Q3 2025. This is likely linked to the company's increased debt levels and financing activities.

Industry Context

Vitro Biopharma operates in the biopharmaceutical sector, a highly competitive and research-intensive industry. Companies in this space often rely on significant capital investment for drug development and face long product development cycles. The industry is characterized by innovation, regulatory hurdles, and the potential for high rewards but also substantial risks.

Regulatory Implications

As a biopharmaceutical company, Vitro Biopharma is subject to stringent regulatory oversight from bodies like the FDA. Compliance with evolving regulations, clinical trial standards, and manufacturing practices is critical. Any failure to comply can lead to significant delays, fines, or product rejection.

What Investors Should Do

1. Scrutinize the drivers of Q3 revenue growth.
2. Analyze the impact of derivative/warrant liability changes.
3. Assess the company's cash runway and future financing needs.
4. Evaluate the terms and potential dilution from convertible notes.

Key Dates

• 2025-07-31: End of Third Quarter Reporting Period — Key period for revenue and loss reporting, showing significant revenue growth but a widening net loss and decreased cash.
• 2024-10-31: Prior Fiscal Year End — Baseline for comparison of cash, liabilities, and stockholders' deficit.
• 2025-07-31: Issuance of 2025 Series Senior Secured Convertible Notes — Indicates significant new financing activity, impacting the company's debt structure and future equity.

Glossary

Derivative/Warrant Liability

A financial obligation that arises from options or warrants, which give the holder the right, but not the obligation, to buy or sell an underlying asset at a specific price. Changes in the value of these instruments can impact the company's net income. (A substantial increase in this liability significantly widened Vitro Biopharma's net loss in Q3 2025.)

Stockholders' Deficit

Occurs when a company's total liabilities exceed its total assets, resulting in a negative net worth for shareholders. (Vitro Biopharma's stockholders' deficit has deepened, indicating a precarious financial position.)

Convertible Notes Payable

Debt instruments that can be converted into a predetermined amount of the issuer's equity (stock) at certain times during their life. (Vitro Biopharma issued a significant amount of convertible notes, which is a key financing strategy but carries potential for future dilution.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Vitro Biopharma has demonstrated impressive revenue growth, with Q3 revenue up 90.2% and year-to-date revenue up 19.2%. However, this top-line improvement has been overshadowed by a significantly widened net loss in Q3 and a substantial increase in derivative/warrant liability. The company's cash position has also deteriorated considerably, while total liabilities have grown, leading to a deeper stockholders' deficit.

Filing Documents

• form10-q.htm (10-Q) — 1495KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001641172-25-027168.txt ( ) — 8339KB
• vtro-20250731.xsd (EX-101.SCH) — 63KB
• vtro-20250731_cal.xml (EX-101.CAL) — 85KB
• vtro-20250731_def.xml (EX-101.DEF) — 240KB
• vtro-20250731_lab.xml (EX-101.LAB) — 507KB
• vtro-20250731_pre.xml (EX-101.PRE) — 360KB
• form10-q_htm.xml (XML) — 1504KB

FINANCIAL INFORMATION

Part I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3 Consolidated Balance Sheets as of July 31, 2025 and October 31, 2024 (unaudited) 3 Consolidated Statements of Operations for the Three Months Ended July 31, 2025 and 2024 (unaudited) 4 Consolidated Statements of Operations for the Nine Months Ended July 31, 2025 and 2024 (unaudited) 5 Consolidated Statements of Changes in Stockholders' Deficit for the Nine Months Ended July 31, 2025 and 2024 (unaudited) 6 Consolidated Statements of Cash Flows for the Nine Months Ended July 31, 2025 and 2024 (unaudited) 7 Notes to Unaudited Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 31

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 42

Controls and Procedures

Item 4. Controls and Procedures 42

OTHER INFORMATION

Part II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 42

Risk Factors

Item 1A. Risk Factors 43

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 43

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 43

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 43

Other Information

Item 5. Other Information 43

Exhibits

Item 6. Exhibits 43

Signatures

Signatures 44 2 PART I-FINANCIAL INFORMATION Item 1. Financial Statements Vitro BioPharma, Inc. Consolidated Balance Sheets (Unaudited) July 31, 2025 October 31, 2024 ASSETS Cash $ 175,081 $ 571,360 Accounts Receivable, Net 209,555 206,292 Accounts Receivable – Related Party 15,750 - Accounts Receivable 15,750 - Inventory 174,072 115,365 Prepaid Expense 70,955 82,736 Total Current Assets 645,413 975,753 Goodwill 3,171,581 3,171,581 Intangible Assets, Net 335,227 358,084 Property and Equipment, Net 57,329 139,552 Patents, Net 155,067 89,548 Right of Use Asset – Operating Lease 255,658 346,091 Other Assets 8,438 8,438 Total Assets $ 4,628,713 $ 5,089,047 LIABILITIES Accounts Payable $ 2,522,552 $ 2,163,920 Accounts Payable – Related Party 22,610 - Deferred Revenue, Net 525,387 525,387 Accrued Liabilities 1,863,630 1,806,419 2021 Series Convertible Note Payable – Related Party - 480,000 Accrued Interest Payable – Related Party 450,914 81,679 2024 Series Senior Secured Convertible Notes Payable – Stock Settled, Net 593,750 4,718,750 2025 Series Senior Secured Convertible Notes Payable – Stock Settled, Net 1,684,876 - Derivative/Warrant Liability 5,154,391 154,966 Unsecured 4% Note Payable – Related Party 1,221,958 - Unsecured 6% Note Payable – Related Party 767,288 - Current Maturities of Capital Lease Obligations 7,704 12,081 Current Maturities of Operating Lease Obligations 111,955 119,486 Total Current Liabilities 14,927,015 10,062,688 Capital Lease Obligations, Net of Current Portion - 5,042 Operating Lease Obligation, Net of Current Portion 143,703 226,605 Unsecured 6% Note Payable – Related Party - 767,288 Unsecured 4% Note Payable – Related Party - 1,221,958 2022 Series Convertible Notes Payable 200,000 200,000 2023 Series Convertible Notes Payable - Stock Settled, Net 363,454 353,114 2023 Series B Convertib

View Full Filing

View this 10-Q filing on SEC EDGAR